Clinical Laserthermia Systems nomination committee appointed
The Nomination Committee of Clinical Laserthermia Systems AB (the "Company" or CLS") has been appointed in accordance with the guidelines for the Nomination Committee adopted at the Annual General Meeting on 29 June 2023.
Members of the Nomination Committee
The following persons have been appointed members of the Nomination Committee for the 2024 Annual General Meeting:
- Karl-Göran Tranberg, representing KG Tranberg Medical AB – owner of class A shares.
- Lars-Erik T. Eriksson, representing Elano AB – owner of class A shares.
- Navin Khattar, representing Group Khattar – owner of class B shares.
- Henrik Nilsson – owner of class B shares.
The Nomination Committee consists of representatives of the two (2) largest Class A shareholders in terms of voting rights and the two (2) largest Class B shareholders.
Duties of the Nomination Committee
The Nomination Committee shall submit proposals for:
- Chairman of the Annual General Meeting,
- the number of members of the Board of Directors and the number of auditors;
- fees and other remuneration to the members of the Board of Directors, members of the Board's various committees and fees to the auditors,
- election of the Chairman of the Board of Directors and other members of the Board of Directors and election of auditors; and
- changes to the instruction for the Nomination Committee.
The Nomination Committee shall notify the Company of its proposals no later than six weeks before the Annual General Meeting. In connection with the nomination committee announcing its proposals to the Company, the nomination committee shall also issue a statement containing the information to be published on the Company's website.
For more information, please contact:
Lars-Erik T. Eriksson, member of the board of directors Clinical Laserthermia Systems AB
Phone: +46 (0)70-290 3300
E-mail: lee@clinicallaser.se
About CLS
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company’s interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB
For more information about CLS, please visit the Company's website: www.clinicallaser.se